We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Johnson and Johnson | NYSE:JNJ | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -0.92 | -0.63% | 145.90 | 147.175 | 145.95 | 146.70 | 6,182,981 | 00:52:45 |
From Apr 2019 to Apr 2024
Biopharmaceutical company Actelion Ltd. said Friday that it had been approached by Johnson & Johnson about a possible deal.
Shares rose 16% to 182.40 Swiss francs on the SIX Swiss Exchange.
J&J didn't immediately respond to a request for comment.
Last year, Switzerland-based Actelion reported revenue of 2.05 billion francs ($2.02 billion) and a profit of 551.9 million francs.
Actelion, which had its initial public offering at the turn of the century, focuses on drugs for pulmonary arterial hypertension, a type of high blood pressure that affects arteries in the lungs and in the heart.
Bloomberg reported Thursday that J&J had made an initial bid for the specialty drug company.
Shares of J&J rose 0.7% to $113.88 in morning trading in the U.S.
Write to Austen Hufford at austen.hufford@wsj.com
(END) Dow Jones Newswires
November 25, 2016 12:05 ET (17:05 GMT)
Copyright (c) 2016 Dow Jones & Company, Inc.
1 Year Johnson and Johnson Chart |
1 Month Johnson and Johnson Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
